|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 238,000.00 KRW | -0.21% |
|
+4.62% | +31.49% |
| 02-05 | CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5) | RE |
| 01-30 | Celltrion Launches Autoimmune Drug Aptozma in Europe | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | ₩251,521.74 | +5.68% | 23 | ||||||
| CHF 676.22 | +26.11% | 23 | ||||||
| US$409.21 | +15.32% | 24 | ||||||
| US$242.55 | +47.5% | 20 | ||||||
| US$121.94 | +21.21% | 18 | ||||||
| €70.86 | +7.33% | 15 | ||||||
| US$240.08 | +27.53% | 16 | ||||||
| US$91.13 | +12% | 22 | ||||||
| US$490.5 | +14.55% | 12 | ||||||
| US$55.23 | +13.27% | 15 | ||||||
| €108.46 | +0.43% | 5 | ||||||
| US$75.25 | +28.63% | 12 | ||||||
| US$85.69 | +63.04% | 13 | ||||||
| US$572.88 | +74.64% | 16 | ||||||
| US$215.73 | +36.08% | 15 | ||||||
| CN¥36.92 | +23.49% | 13 | ||||||
| CN¥68.9 | +13.18% | 11 | ||||||
| US$162.21 | +83.04% | 14 | ||||||
| US$116.71 | +37.57% | 21 | ||||||
| Average | 13,440.12 | +28.98% | 16 | ||||||
| Weighted average by Cap. | 29,729.59 | +24.90% | 19 |
- Stock Market
- Equities
- A068270 Stock
- Sector Celltrion, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition